« Media center

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland

Helsinn Healthcare SA

Swiss approval of ALOXI®􀀃for paediatric use follows EMA approval in

February 2015 and FDA approval in May 2014

Lugano and Villars-sur-Glâne, Switzerland, October 25th, 2016: Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Vifor Pharma, announced today that Swissmedic, the Swiss Agency For Therapeutic Products, has approved ALOXI®, an anti-nausea therapeutic medicine for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients one month of age and older. The approval was granted on 19 August 2016.

Read the complete presse release: